allopurinol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   61 Trials   61 Trials   3860 News 


«12...1617181920212223242526...5758»
  • ||||||||||  colchicine / Generic mfg., allopurinol / Generic mfg.
    Journal:  Pharmacist knowledge of gout management: impact of an educational intervention. (Pubmed Central) -  May 25, 2022   
    Pharmacists are a valuable information resource for patients. Co-designing a brief education intervention with pharmacists is an effective, low-cost way to increase pharmacist knowledge on the management of gout.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Prevalence of Hypertension in Sudanese Patients With Gouty Arthritis. (Pubmed Central) -  May 24, 2022   
    The most frequently used uric acid lowering agent was found to be allopurinol in 85% of the patients...Moreover, the male gender was a significant risk factor for hypertension among the gouty arthritis participants. Nevertheless, most patients with high blood pressure levels had concurrent elevated uric acid levels.
  • ||||||||||  probenecid / Generic mfg., allopurinol / Generic mfg.
    ASYMPTOMATIC HYPERURICEMIA AND ASSOCIATED FACTORS IN MALE PATIENTS VISITED HANOI MEDICAL UNIVERSITY HOSPITAL () -  May 24, 2022 - Abstract #EULAR2022EULAR_4001;    
    Exclude criteria included patients having medicine which affected serum uric acid (allopurinol, probenecid, sulfinpyrazone, salicylate, phenylbutazone, ascorbic acid, ethambutol, pyrazinamide, ect.), had acute diseases, diabetes type 1, chronic kidney disease and malignancies. Alcohol consuming, dyslipidemia and hypertension were associated with higher risk of incident asymptomatic hyperuricemia in Vietnamese men.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA () -  May 24, 2022 - Abstract #EULAR2022EULAR_3997;    
    In patients with pre-dialysis stages of CKD, the use of febuxostat is accompanied by stabilization or increase in GFR. Use of febuxostat in patients with CKD stage 3b-4 and in patients on hemodialysis is safe and more effective for target sUA level achievement than the use of allopurinol.
  • ||||||||||  colchicine / Generic mfg., febuxostat / Generic mfg., allopurinol / Generic mfg.
    EVALUATION OF THE EFFECTIVENESS OF GOUT THERAPY IN OUTPATIENT PRACTICE () -  May 24, 2022 - Abstract #EULAR2022EULAR_3996;    
    This study proves that achieving the target level of UA is possible in most patients with gout, leads to a significant reduction in the number of attacks and their severity, requires educational work and patient monitoring. It is important that this work is part of a planned 2-year follow-up of patients with gout in order to determine the long-term effectiveness of therapy.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    GENDER DIFFERENCES IN TAKING XANTHIOXIDASE INHIBITORS IN GOUT () -  May 24, 2022 - Abstract #EULAR2022EULAR_3989;    
    Due to the marked increase in the uric acid level, men develop more severe joint damage because of the tendency to chronicity. However, the study did not reveal gender differences in the response to XO inhibitors, which indicates that there is no need to choose therapy depending on the patient’s gender.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    ASSOCIATION OF Q141K POLYMORPHISM OF ABCG2 GENE WITH THE EFFECTIVENESS OF URATE-LOWERING THERAPY IN PATIENTS WITH GOUT (PILOT STUDY) () -  May 24, 2022 - Abstract #EULAR2022EULAR_3974;    
    Objectives: To study the opportunity of the target sUA level achievement in pts with gout while taking allopurinol or febuxostat, depending on the polymorphism (rs2231142) of the ABCG2 gene. The opportunity of achieving the target sUA level in pts with gout taking allopurinol is not associated with the C>A polymorphism of the ABCG2 gene, but the presence of the CA and AA genotypes is associated with the need to prescribe large doses of allopurinol.
  • ||||||||||  allopurinol / Generic mfg.
    Review, Journal, Adverse drug reaction:  The assessment of severe cutaneous adverse drug reactions. (Pubmed Central) -  May 21, 2022   
    Allopurinol, antibiotics and anticonvulsants are often implicated...Any decision to reintroduce a drug should be made after considering the harm-benefit ratio. Caution is also needed if considering a possibly cross-reactive drug in a patient with a history of severe cutaneous adverse drug reactions.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives. (Pubmed Central) -  May 19, 2022   
    Further studies are also required to assess whether melatonin, neurosteroids, inhaled nitric oxide, allopurinol, or dietary supplements (omega-3 fatty acids, choline, curcumin, etc.) could be implemented as neuroprotectants in clinical practice...· Follow-up of infants treated with erythropoietin is needed.. · Neuroprotective efficacy of several drugs in animals needs to be shown in humans..
  • ||||||||||  allopurinol / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy:  Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) (clinicaltrials.gov) -  May 17, 2022   
    P1/2,  N=30, Not yet recruiting, 
    Present investigation demonstrated that ANPs prepared from low MW chitosan depicted maximum kidney-targeting ability that might be due to its specific uptake by the kidneys as well as its higher solubility than other two polymers, which results in enhanced release rate from the formulation and also offers an efficient strategy for the management of hyperuricemic nephrolithiasis. Trial completion date: Jan 2024 --> Jul 2024 | Initiation date: Mar 2022 --> Sep 2022 | Trial primary completion date: Jul 2023 --> Jan 2024
  • ||||||||||  Review, Journal:  Patch testing in Drug reaction with eosinophilia and systemic symptoms (DRESS): a literature review. (Pubmed Central) -  May 15, 2022   
    By far, the most reactions (n = 145) were caused by carbamazepine, followed by amoxicillin, isoniazid, phenytoin, ethambutol, fluindione, phenobarbital, rifampicin, and ceftriaxone; 43 drugs each caused a single case only...Allopurinol and sulfasalazine frequently cause DRESS but never give positive patch tests...Multiple drug hypersensitivity was found to occur in 16% of all patients, but it is argued that the true frequency is (far) higher. Clinical aspects of DRESS, including diagnosing the disease and identifying culprit drugs (patch tests, intradermal tests, in vitro tests, challenge tests) are also provided, emphasizing the role of patch testing.
  • ||||||||||  Biomarker, Review, Journal, Adverse drug reaction, IO biomarker:  An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. (Pubmed Central) -  May 14, 2022   
    Recent pharmacogenomic studies have demonstrated the strong associations between severe ADR and genetic markers, including specific HLA alleles (e.g., HLA-B*15:02/HLA-B*57:01/HLA-A*31:01 for carbamazepine-induced severe cutaneous adverse drug reactions [SCAR], HLA-B*58:01 for allopurinol-SCAR, HLA-B*57:01 for abacavir-hypersensitivity, HLA-B*13:01 for dapsone/co-trimoxazole-induced SCAR, and HLA-A*33:01 for terbinafine-induced liver injury), drug metabolism enzymes (such as CYP2C9*3 for phenytoin-induced SCAR and missense variant of TPMT/NUDT15 for thiopurine-induced leukopenia), drug transporters (e.g., SLCO1B1 polymorphism for statin-induced myopathy), and T cell receptors (Sulfanilamide binding into the CDR3/Vα of the TCR 1.3). This mini review article aims to summarize the current knowledge of pharmacogenomics of severe ADR, and the potentially clinical use of these genetic markers for avoidance of ADR.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  The Impact of Long-Duration Exposure to Microgravity and Galactic Cosmic Radiation on Corpus Cavernosum Function. (Pubmed Central) -  May 14, 2022   
    Incubation of the CC tissue with the xanthine oxidase inhibitor allopurinol, the mitochondria-targeted antioxidant mito-TEMPO, and the superoxide dismutase (SOD) mimetic TEMPOL increased the relaxation response of the erectile tissue for the groups exposed to radiation, with little or opposite effect on the groups under no radiation exposure...Comparably, western blot analysis showed increased levels of oxidative stress and lipid peroxidation in the corpus cavernosum on the groups under radiation exposure by assessment of 4-hydroxynonenal (HNE), as well as higher levels of arginase 1 and 2. This information suggests that increased oxidative stress from radiation exposure in long spaceflight trips impairs corpus cavernosum vasoreactivity and exposes new factors to consider with space exploration to ensure that astronauts can return to normal life after long trips in space.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Discovery of mycotoxin alternariol as a potential lead compound targeting xanthine oxidase. (Pubmed Central) -  May 12, 2022   
    The potency of XO inhibition by AOH was >12-fold higher as compared to allopurinol (2.98 ± 0.07 μM), a XO inhibitor that has been used clinically...Follow-up docking studies showed that Gln957, Lys1257, and Phe1153 played an important role by forming hydrogen bonds with AOH. Our findings suggest that AOH may be used as a lead compound for further modification to develop future drug for treating hyperuricemia.
  • ||||||||||  allopurinol / Generic mfg.
    Normalizing Glomerular Filtration Rate (GFR) Using Extracellular Volume (ECV) Instead of Body Surface Area (BSA): Results from an Analysis of the Preventing Early Renal Loss (PERL) Trial (Poster Hall (Halls D-E); Board No. 391) -  May 11, 2022 - Abstract #ADA2022ADA_1048;    
    In this exploratory analysis of the PERL clinical trial of allopurinol, the distribution and agreement of 4 measurements for GFR were compared in 542 participants with eligible data...These data show that ECV calculation and GFR standardization by ECV are feasible, providing similar measure of GFR as compared to BSA adjustments, although PERL trial outcomes were not affected by the method used to normalize GFR. Future studies are needed to determine if ECV can be used as an outcome measure for renal interventions, including those that are affected by natriuresis and measures of circulating volume.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Effects of uric acid-lowering therapy in patients with essential arterial hypertension. (Pubmed Central) -  May 10, 2022   
    In patients with AH and AHU, treatment with allopurinol leads to improvement in BP control and reduction in HMOD intensity, in particular IMT. The decrease in hs-CRP concentration associated with ULT may have a beneficial effect on a patient's long-term prognosis.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Review, Journal:  Update on Uric Acid and the Kidney. (Pubmed Central) -  May 10, 2022   
    This may push other studies to administer higher dosages per ACR guidelines. Future studies could then demonstrate decreased progression of CKD.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  "In silico identification of ethoxy phthalimide pyrazole derivatives as IL-17A and IL-18 targeted gouty arthritis agents". (Pubmed Central) -  May 10, 2022   
    Compound 3e had the lowest binding energy with IL17A at -12.6 kcal/mol compared to control allopurinol (3.32 kcal/mol)...Depending on properties of the bound IL17A-3a and IL18-3a complexes was compared by means of MM-PBSA analysis. These derivatives can be used as a scaffold to develop promising IL17A and IL18 inhibitors to assess their potential for gouty arthritis and other related diseases.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt. (Pubmed Central) -  May 9, 2022   
    Male Sprague-Dawley rats were divided into normal saline, disease group by injecting potassium mono-oxonate (PO) at a dose of 250 mg/kg, and three treatment groups, either with carvacrol 20 mg/kg or 50 mg/kg and 10 mg/kg allopurinol...Furthermore, the renal safety of carvacrol was confirmed by the renal function test. Carvacrol potentially alleviates hyperuricemia-induced oxidative stress and inflammation by regulating the ROS/NRLP3/NF-κB pathway, thereby exerting protective effects against joint degeneration.
  • ||||||||||  Kineret (anakinra) / SOBI
    Can doctors treat gout well? Insight on gout management in referral centres (Poster View 8) -  May 6, 2022 - Abstract #EULAR2022EULAR_2558;    
    Simple application of gout management guidelines is feasible in clinical practice, and is efficient with a majority of patients achieving SU targets and clinical improvement. A minority of patients in referral centres have ‘difficult-to-treat’ gout requiring specific management.
  • ||||||||||  colchicine / Generic mfg., febuxostat / Generic mfg., allopurinol / Generic mfg.
    Characterization of gout in US patients undergoing hemodialysis (HD) and peritoneal dialysis (PD) (Poster View 8) -  May 6, 2022 - Abstract #EULAR2022EULAR_2555;    
    The true prevalence of gout was likely higher than observed when considering potential under-ascertainment of gout diagnosis history in nephrology/dialysis-focused clinical settings. 3 This report provides a snapshot of gout in the US dialysis population and offers opportunities to expand on research to improve awareness and care for patients with gout and ESRD.
  • ||||||||||  D-0120 / InventisBio
    Trial completion date:  Evaluation of PK and Safety of D-0120 and Allopurinol (clinicaltrials.gov) -  May 6, 2022   
    P1,  N=20, Active, not recruiting, 
    3 This report provides a snapshot of gout in the US dialysis population and offers opportunities to expand on research to improve awareness and care for patients with gout and ESRD. Trial completion date: Apr 2022 --> Jul 2022
  • ||||||||||  allopurinol / Generic mfg.
    Effect of Allopurinol Versus Saline Hydration in Preventing Contrast-Induced Nephropathy (Mini-Orals Hall) -  May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1171;    
    No other significant difference noted across all groups ( P >0.05 in all cases). CONCLUSION CIN developed in a significantly lesser number of patients who received a single dose of 30 mg of Allopurinol 12 h before administration of contrast along with saline hydration as compared with patients receiving hydration alone.
  • ||||||||||  allopurinol / Generic mfg.
    Clinical Features of Allopurinol-Induced DRESS/DIHS in 46 Patients (Mini-Orals Hall) -  May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_933;    
    Treatment and outcome of allopurinol-induced DRESS patients a Many patients received a combination of the above-listed therapies. b Outcomes were known for 45 of the 46 patients.